Bristol-Myers Squibb has discontinued Daklinza (daclatasvir) in markets where it is no longer routinely prescribed, and there are other therapeutic options available. Daklinza played a significant role in providing a new era of treatment, offering patients across the globe the potential for cure from chronic HCV infection. New Hepatitis C treatments have built on the safety and efficacy profile of Daklinza to offer shorter treatment durations and a reduced pill burden, and thus providing patients more options for a potential cure.
Following the lapse of marketing authorization in each market, the patents in that market will also be allowed to lapse. In the interim period between the lapse of a marketing authorization and patent expiry, Bristol-Myers Squibb will not enforce its patents in that market. This policy is specific for Daklinza moving forward.
For questions, please contact the BMS Medical Information Department. Local contact information can be found at: http://www.globalbmsmedinfo.com/